tradingkey.logo

Transmedics Group Inc

TMDX
127.670USD
+6.600+5.45%
收盘 12/19, 16:00美东报价延迟15分钟
4.36B总市值
47.17市盈率 TTM

Transmedics Group Inc

127.670
+6.600+5.45%

关于 Transmedics Group Inc 公司

TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.

Transmedics Group Inc简介

公司代码TMDX
公司名称Transmedics Group Inc
上市日期May 02, 2019
CEOHassanein (Waleed H)
员工数量728
证券类型Ordinary Share
年结日May 02
公司地址200 Minuteman Road
城市ANDOVER
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编01810
电话19785520900
网址https://www.transmedics.com/
公司代码TMDX
上市日期May 02, 2019
CEOHassanein (Waleed H)

Transmedics Group Inc公司高管

名称
名称/职务
职务
持股
持股变动
Dr. Waleed H. Hassanein, M.D.
Dr. Waleed H. Hassanein, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
481.61K
-8.98%
Mr. James R. Tobin
Mr. James R. Tobin
Independent Chairman of the Board
Independent Chairman of the Board
177.21K
+1.22%
Dr. David Weill, M.D.
Dr. David Weill, M.D.
Independent Director
Independent Director
12.13K
--
Mr. Nicholas (Nick) Corcoran
Mr. Nicholas (Nick) Corcoran
Senior Vice President - Supply Chain and Operations
Senior Vice President - Supply Chain and Operations
7.04K
-44.49%
Ms. Merilee Raines, CPA
Ms. Merilee Raines, CPA
Independent Director
Independent Director
4.06K
+110.86%
Ms. Stephanie Lovell
Ms. Stephanie Lovell
Independent Director
Independent Director
4.06K
+110.86%
Mr. Thomas James Gunderson
Mr. Thomas James Gunderson
Independent Director
Independent Director
4.06K
+110.86%
Mr. Gerardo Hernandez
Mr. Gerardo Hernandez
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
331.00
-97.93%
Mr. Anil Ranganath
Mr. Anil Ranganath
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
--
--
Mr. Edwin M. Kania, Jr.
Mr. Edwin M. Kania, Jr.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Waleed H. Hassanein, M.D.
Dr. Waleed H. Hassanein, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
481.61K
-8.98%
Mr. James R. Tobin
Mr. James R. Tobin
Independent Chairman of the Board
Independent Chairman of the Board
177.21K
+1.22%
Dr. David Weill, M.D.
Dr. David Weill, M.D.
Independent Director
Independent Director
12.13K
--
Mr. Nicholas (Nick) Corcoran
Mr. Nicholas (Nick) Corcoran
Senior Vice President - Supply Chain and Operations
Senior Vice President - Supply Chain and Operations
7.04K
-44.49%
Ms. Merilee Raines, CPA
Ms. Merilee Raines, CPA
Independent Director
Independent Director
4.06K
+110.86%
Ms. Stephanie Lovell
Ms. Stephanie Lovell
Independent Director
Independent Director
4.06K
+110.86%

收入明细

单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
OCS Liver net revenue
116.11M
74.26%
OCS Heart net revenue
35.67M
22.81%
OCS Lung net revenue
4.58M
2.93%
地区USD
名称
营收
占比
United States
152.19M
97.34%
All other countries
4.16M
2.66%
业务
地区
业务USD
名称
营收
占比
OCS Liver net revenue
116.11M
74.26%
OCS Heart net revenue
35.67M
22.81%
OCS Lung net revenue
4.58M
2.93%

股东统计

更新时间: 11月25日 周二
更新时间: 11月25日 周二
持股股东
股东类型
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
13.86%
Fidelity Management & Research Company LLC
13.45%
The Vanguard Group, Inc.
10.53%
State Street Investment Management (US)
3.74%
Two Sigma Investments, LP
3.10%
其他
55.32%
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
13.86%
Fidelity Management & Research Company LLC
13.45%
The Vanguard Group, Inc.
10.53%
State Street Investment Management (US)
3.74%
Two Sigma Investments, LP
3.10%
其他
55.32%
股东类型
持股股东
占比
Investment Advisor
71.86%
Investment Advisor/Hedge Fund
23.66%
Hedge Fund
7.08%
Research Firm
4.62%
Individual Investor
2.95%
Bank and Trust
2.15%
Pension Fund
1.35%
Sovereign Wealth Fund
0.18%
Insurance Company
0.10%

机构持股

更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
762
37.62M
110.09%
-8.17M
2025Q2
746
42.27M
124.01%
-2.30M
2025Q1
751
42.32M
125.08%
-2.32M
2024Q4
728
40.09M
119.11%
-642.74K
2024Q3
673
39.30M
117.10%
+1.37M
2024Q2
615
36.53M
110.85%
-3.27M
2024Q1
544
37.44M
113.97%
-4.28M
2023Q4
512
38.18M
116.94%
-3.46M
2023Q3
482
38.42M
117.77%
-240.92K
2023Q2
462
35.43M
108.88%
-81.81K
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
BlackRock Institutional Trust Company, N.A.
4.73M
13.87%
-97.24K
-2.02%
Jun 30, 2025
Fidelity Management & Research Company LLC
4.63M
13.57%
-32.85K
-0.71%
Jun 30, 2025
The Vanguard Group, Inc.
3.59M
10.53%
+21.12K
+0.59%
Jun 30, 2025
State Street Investment Management (US)
1.29M
3.78%
-17.52K
-1.34%
Jun 30, 2025
Two Sigma Investments, LP
692.64K
2.03%
+666.54K
+2554.00%
Jun 30, 2025
Nomura Investment Management Business Trust
952.11K
2.79%
-163.49K
-14.66%
Jun 30, 2025
Geode Capital Management, L.L.C.
804.65K
2.36%
+11.24K
+1.42%
Jun 30, 2025
Driehaus Capital Management, LLC
854.04K
2.51%
+75.28K
+9.67%
Jun 30, 2025
Hood River Capital Management LLC
679.85K
1.99%
-115.92K
-14.57%
Jun 30, 2025
Emerald Advisers LLC
694.97K
2.04%
-22.39K
-3.12%
Jun 30, 2025
查看更多

持股ETF

更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
Global X HealthTech ETF
4.75%
Clough Select Equity ETF
2.87%
Invesco S&P SmallCap Health Care ETF
2.75%
State Street SPDR S&P Health Care Equipment ETF
2.18%
Invesco S&P SmallCap 600 Pure Growth ETF
1.54%
First Trust Nasdaq Lux Digi Health Solutions ETF
1.47%
iShares S&P Small-Cap 600 Growth ETF
0.63%
State Street SPDR S&P 600 Small Cap Growth ETF
0.61%
First Trust Multi-Manager Small Cap Opportunities ETF
0.58%
Vanguard S&P Small-Cap 600 Growth Index Fund
0.58%
查看更多
Global X HealthTech ETF
占比4.75%
Clough Select Equity ETF
占比2.87%
Invesco S&P SmallCap Health Care ETF
占比2.75%
State Street SPDR S&P Health Care Equipment ETF
占比2.18%
Invesco S&P SmallCap 600 Pure Growth ETF
占比1.54%
First Trust Nasdaq Lux Digi Health Solutions ETF
占比1.47%
iShares S&P Small-Cap 600 Growth ETF
占比0.63%
State Street SPDR S&P 600 Small Cap Growth ETF
占比0.61%
First Trust Multi-Manager Small Cap Opportunities ETF
占比0.58%
Vanguard S&P Small-Cap 600 Growth Index Fund
占比0.58%

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据

常见问题

Transmedics Group Inc的前五大股东是谁?

Transmedics Group Inc 的前五大股东如下:
BlackRock Institutional Trust Company, N.A.持有股份:4.73M,占总股份比例:13.87%。
Fidelity Management & Research Company LLC持有股份:4.63M,占总股份比例:13.57%。
The Vanguard Group, Inc.持有股份:3.59M,占总股份比例:10.53%。
State Street Investment Management (US)持有股份:1.29M,占总股份比例:3.78%。
Two Sigma Investments, LP持有股份:692.64K,占总股份比例:2.03%。

Transmedics Group Inc的前三大股东类型是什么?

Transmedics Group Inc 的前三大股东类型分别是:
BlackRock Institutional Trust Company, N.A.
Fidelity Management & Research Company LLC
The Vanguard Group, Inc.

有多少机构持有Transmedics Group Inc(TMDX)的股份?

截至2025Q3,共有762家机构持有Transmedics Group Inc的股份,合计持有的股份价值约为37.62M,占公司总股份的110.09%。与2025Q2相比,机构持股有所增加,增幅为-13.93%。

哪个业务部门对Transmedics Group Inc的收入贡献最大?

在FY2025Q2,OCS Liver net revenue业务部门对Transmedics Group Inc的收入贡献最大,创收116.11M,占总收入的74.26%。
KeyAI